MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 584441 | Name: Cefazedone
Featured

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Cefazedone is a semisynthetic first-generation cephalosporin with antibacterial activity.

Chemical Structure

Cefazedone
Cefazedone
CAS#56187-47-4 (free base)

Theoretical Analysis

MedKoo Cat#: 584441

Name: Cefazedone

CAS#: 56187-47-4 (free base)

Chemical Formula: C18H15Cl2N5O5S3

Exact Mass: 546.9612

Molecular Weight: 548.43

Elemental Analysis: C, 39.42; H, 2.76; Cl, 12.93; N, 12.77; O, 14.59; S, 17.54

Price and Availability

Size Price Availability Quantity
25mg USD 350.00 2 Weeks
50mg USD 550.00 2 Weeks
100mg USD 950.00 2 Weeks
Bulk Inquiry
Buy Now
Add to Cart
Related CAS #
63521-15-3 (sodium) 56187-47-4 (free base)
Synonym
Cefazedone; Refosporen, Cefazedonum
IUPAC/Chemical Name
(6R,7R)-7-(2-(3,5-Dichloro-4-oxo-1(4H)-pyridyl)acetamido)-3-(((5-methyl-1,3,4-thiadiazol-2-yl)thio)methyl)-8-oxo-5-thia-1-azabicyclo(4.2.0)-oct-2-ene-2-carboxylic acid
InChi Key
VTLCNEGVSVJLDN-MLGOLLRUSA-N
InChi Code
InChI=1S/C18H15Cl2N5O5S3/c1-7-22-23-18(33-7)32-6-8-5-31-16-12(15(28)25(16)13(8)17(29)30)21-11(26)4-24-2-9(19)14(27)10(20)3-24/h2-3,12,16H,4-6H2,1H3,(H,21,26)(H,29,30)/t12-,16-/m1/s1
SMILES Code
O=C(C(N12)=C(CSC3=NN=C(C)S3)CS[C@]2([H])[C@H](NC(CN(C=C4Cl)C=C(Cl)C4=O)=O)C1=O)O
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>2 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info

Preparing Stock Solutions

The following data is based on the product molecular weight 548.43 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
1: Wu D, Qian ZY, Guo T, Tang W, Xiang Y, Zheng H. Determination of cefazedone in human plasma by high performance liquid chromatography-tandem mass spectrometry: Application to a pharmacokinetic study on Chinese volunteers. J Chromatogr B Analyt Technol Biomed Life Sci. 2010 Oct 15;878(28):2911-5. doi: 10.1016/j.jchromb.2010.08.008. Epub 2010 Aug 17. PMID: 20813593. 2: Gao L, Zhu Y, Lyu Y, Hao FL, Zhang P, Wei MJ. A Pharmacokinetic and Pharmacodynamic Study on Intravenous Cefazedone Sodium in Patients with Community-acquired Pneumonia. Chin Med J (Engl). 2015 May 5;128(9):1160-4. doi: 10.4103/0366-6999.156086. PMID: 25947397; PMCID: PMC4831541. 3: Adam D, Hofstetter AG, Reichart B, Schneider C, Wolff H, Koch E. Zur Diffusion von Cefazedon in das Herzmuskel-, Prostata- und Hautgewebe sowie in die Gallenflüssigkeit [The diffusion of cefazedone into heart muscle, prostatic and skin tissue and into bile]. Arzneimittelforschung. 1979;29(12):1901-6. German. PMID: 546431. 4: Bloom JC, Lewis HB, Sellers TS, Deldar A. The hematologic effects of cefonicid and cefazedone in the dog: a potential model of cephalosporin hematotoxicity in man. Toxicol Appl Pharmacol. 1987 Aug;90(1):135-42. doi: 10.1016/0041-008x(87)90314-0. PMID: 3629586. 5: Cui Y, Ma N, Li X, Lv C, Li M, Li M, Song L, Liu M, Li Q, Bi K. Development of an ultra fast liquid chromatography-tandem mass spectrometry method for simultaneous determination of cefazedone and etimicin in beagle dog plasma: Application to the pharmacokinetic study of the combination of cefazedone and etimicin injections. J Chromatogr B Analyt Technol Biomed Life Sci. 2014 Dec 15;973C:97-103. doi: 10.1016/j.jchromb.2014.10.018. Epub 2014 Oct 23. PMID: 25464101. 6: Mondorf AW. Investigations on the potential nephrotoxicity of cefazedone and gentamicin and of their combination, in comparison with the combination of cefazolin and cephalothin with gentamicin. Arzneimittelforschung. 1979;29(2a):449-52. PMID: 582724. 7: Bergmann R, Wahlig H, Mitsuhashi S. Comparison of cefazedone with cefazolin and cephalothin in treatment of experimental infections in mice. Arzneimittelforschung. 1979;29(2a):412-4. PMID: 582716. 8: Pabst J, Leopold G, Ungethüm W, Dingeldein E. Clinical pharmacology phase I of cefazedone, a new cephalosporin, in healthy volunteers. II. Pharmacokinetics in comparison with cefazolin. Arzneimittelforschung. 1979;29(2a):437-43. PMID: 582722. 9: Primavesi CA. In vitro studies with cefazedone. Arzneimittelforschung. 1979;29(2a):381-4. PMID: 582713. 10: Koch E, Wiemann H, Empl I. Cefazedon--Ergebnisse einer multizentrischen klinischen Studie [Cefazedone-results of a multicentre clinical test (author's transl)]. MMW Munch Med Wochenschr. 1980 Mar 21;122(12):431-4. German. PMID: 6769007. 11: Russell AD, Rogers DT. In vitro activity of cefazedone, a new cephalosporin antibiotic. J Antimicrob Chemother. 1980 Mar;6(2):288-91. doi: 10.1093/jac/6.2.288. PMID: 6966627. 12: von Kobyletzki D, Primavesi CA, Koch E. Cefazedon bei infektiösen Erkrankungen in der Frauenheilkunde Klinische Prüfung zur Wirksamkeit und Verträglichkeit [Cefazedone in infectious diseases in gynecology. Clinical tests on efficacy and tolerance]. Fortschr Med. 1979 Feb 1;97(5):214-8. German. PMID: 372073. 13: Koch E, Friese J, Debuch KE. Clinical evaluation of cefazedone. Arzneimittelforschung. 1979;29(2a):456-60. PMID: 582726. 14: Schöpf E. Investigations on group allergy reactions to cefazedone in patients with penicillin allergy of the anaphylactic type (type I) and of the delayed type (type IV). Arzneimittelforschung. 1979;29(2a):461-2. PMID: 582727. 15: Wahlig H, Dingeldein E, Mitsuhashi S, Kawabe H. Cefazedone: microbiological evaluation in comparison with cephalothin and cefazolin. Arzneimittelforschung. 1979;29(2a):369-78. PMID: 582712. 16: Dingeldein E, Wahlig H. Blood levels and tissue concentrations of cefazedone in animals. Arzneimittelforschung. 1979;29(2a):400-3. PMID: 582715. 17: Ungethüm W, Leopoid G. Clinical pharmacology phase I of cefazedone, a new cephalosporin, in healthy volunteers. I. Tolerance in comparison with cefazolin. Arzneimittelforschung. 1979;29(2a):435-6. PMID: 582721. 18: Dingeldein E, Wahlig H. MIC determination, disc sensitivity testing, and analysis of regression in cefazedone and cefazolin. Arzneimittelforschung. 1979;29(2a):384-7. PMID: 582714. 19: Züllich B, Sack K. Clinical study on the tolerance of cefazedone. Arzneimittelforschung. 1979;29(2a):453-6. PMID: 582725. 20: Bloom JC, Thiem PA, Sellers TS, Deldar A, Lewis HB. Cephalosporin-induced immune cytopenia in the dog: demonstration of erythrocyte-, neutrophil-, and platelet-associated IgG following treatment with cefazedone. Am J Hematol. 1988 Jun;28(2):71-8. doi: 10.1002/ajh.2830280202. Erratum in: Am J Hematol 1988 Dec;29(4):241. PMID: 3394717.